Cargando…
Did COVID-19 disrupt surgery for patients with pancreatic and hepatic malignancies?
Autores principales: | Manzella, A., Eskander, M.F., Grandhi, M.S., In, H., Langan, R.C., Kennedy, T., August, D., Alexander, H.R., Beninato, T., Pitt, H.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279479/ http://dx.doi.org/10.1016/j.hpb.2023.05.041 |
Ejemplares similares
-
How did COVID-19 influence use of neoadjuvant therapy before surgery for patients with HPB cancers?
por: Manzella, A., et al.
Publicado: (2023) -
Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts
por: Greendyk, Joshua D., et al.
Publicado: (2023) -
Subcategorizing T1 Staging in Pancreatic Adenocarcinoma Predicts Survival in Patients Undergoing Resection: An Analysis of the National Cancer Database
por: Shah, Mihir M., et al.
Publicado: (2020) -
Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database
por: Greco, Stephanie H., et al.
Publicado: (2020) -
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research
por: Kumar, Ritesh, et al.
Publicado: (2023)